Bispecific Antibodies Market

1
Global Bispecific Antibodies Market Is Estimated
To Witness High Growth Owing To Increasing Demand
For Targeted Therapies And Advancements in
Biotechnology

• Bispecific Antibodies Market
• The global Bispecific Antibodies Market is
  estimated to be valued at USD 0.52 Bn in 2022 and
  is expected to exhibit a CAGR of 7.0 over the
  forecast period 2023-2030, as highlighted in a
  new report published by Coherent Market Insights.
• Market Overview
• Bispecific antibodies are innovative therapeutic
  molecules that can simultaneously bind to two
  different antigens, leading to enhanced targeting
  of specific cells and improved efficacy. These
• antibodies have the potential to revolutionize
  the treatment of various diseases, including
  cancer, autoimmune disorders, and infectious
  diseases. The market is witnessing significant
  growth due to the increasing demand for targeted
  therapies and advancements in biotechnology.
  Bispecific antibodies offer several advantages
  over traditional monoclonal antibodies, such as
  enhanced specificity and reduced off-target
  effects. They have the potential to improve
  patient outcomes and provide personalized
  treatment options.
• Market Dynamics
• The market dynamics for the Bispecific Antibodies
  Market can be attributed to two drivers
• Increasing Demand for Targeted Therapies
• There is a growing demand for targeted therapies
  in the healthcare industry, especially for the
  treatment of cancer. Bispecific antibodies have
  the ability to specifically target cancer cells
  and activate the immune system to destroy these
  cells. This targeted approach minimizes damage to
  healthy cells and reduces side effects. For
  example, Amgen, Inc.'s bispecific antibody,
  blinatumomab, has been approved for the treatment
  of acute lymphoblastic leukemia (ALL) and has
  shown significant improvements in patient
  outcomes.
• Advancements in Biotechnology
• The field of biotechnology has witnessed
  considerable advancements in recent years,
  leading to the development of novel therapeutic
  molecules like bispecific antibodies. These
  advancements
• include improvements in antibody engineering
  techniques, such as antibody fragment-based

2

• approaches, recombinant DNA technology, and
  protein engineering. These advancements have
  facilitated the development of bispecific
  antibodies with improved efficacy and reduced
  immunogenicity. For instance, Immunocore
  Limited's bispecific antibody, IMCgp100, has
  shown promising results in clinical trials for
  the treatment of metastatic uveal melanoma.
• Segment Analysis
• The Bispecific Antibodies Market can be segmented
  based on application, end-user, and region. Based
  on application, the oncology segment is expected
  to dominate the market due to the high prevalence
  of cancer and the increasing demand for targeted
  therapies. The oncology segment is further
  divided into solid tumors and hematological
  malignancies, with solid tumors emerging as the
  dominating sub-segment. This can be attributed to
  the rising number of patients with solid tumors
  and the increasing research and development
  activities in this field.
• PEST Analysis
• Political The political environment plays a
  crucial role in the growth of the Bispecific
  Antibodies Market. Regulatory policies and
  approvals for therapeutic molecules can impact
  the market
• dynamics.
• Economic The economic factors, such as
  healthcare expenditure and affordability, can
  influence the adoption of bispecific antibodies.
  The cost-effectiveness of these therapies is an
  important consideration for their widespread use.
• Social The social factors, including the
  increasing prevalence of diseases, aging
  population, and patient awareness, can drive the
  demand for bispecific antibodies.
• Technological Technological advancements in
  biotechnology have played a significant role in
  the development of bispecific antibodies.
  Approaches like antibody engineering and protein
  engineering have improved the efficacy and
  specificity of these therapeutic molecules.
• Key Takeaways
• The global Bispecific Antibodies Market is
  expected to witness high growth, exhibiting a
  CAGR of 7.0 over the forecast period, due to the
  increasing demand for targeted therapies and
  advancements in biotechnology.
• The Asia-Pacific region is expected to be the
  fastest-growing and dominating region, driven by
  the increasing prevalence of chronic diseases,
  rising healthcare expenditure, and growing
  investments in research and development
  activities.
• Key players operating in the global Bispecific
  Antibodies Market are Amgen, Inc., Bayer AG,